Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.

@article{Hagiwara2013ImpactOP,
  title={Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.},
  author={Satoru Hagiwara and Masatoshi Kudo and Yukio Osaki and Hiroo Matsuo and Tadashi Inuzuka and Akihiro Matsumoto and Eiji Tanaka and Toshiharu Sakurai and Kazuomi Ueshima and Tatsuo Inoue and Norihisa Yada and Naoshi Nishida},
  journal={Journal of medical virology},
  year={2013},
  volume={85 6},
  pages={987-95}
}
The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) α-2b and entecavir hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with… CONTINUE READING